^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Xolremdi (mavorixafor)

    i
    Other names: X4P-001, AMD11070, AMD-070, AMD-11070, X4P001, X4P 001, X4P-001-RD, X4P-001-IO, AMD11070 - WHIM, ABSK-081, ABSK081
    Company:
    Abbisko, Norgine, X4 Pharma, taiba
    Drug class:
    CXCR4 antagonist
    Related drugs:
    21d
    A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections (clinicaltrials.gov)
    P3, N=176, Recruiting, X4 Pharmaceuticals | Trial completion date: Aug 2026 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Xolremdi (mavorixafor)
    4ms
    Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome (clinicaltrials.gov)
    P3, N=31, Active, not recruiting, X4 Pharmaceuticals | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor)
    5ms
    Drug-Drug Interaction Potential of Mavorixafor (clinicaltrials.gov)
    P1, N=38, Completed, X4 Pharmaceuticals | Recruiting --> Completed
    Trial completion
    |
    Xolremdi (mavorixafor)
    7ms
    Synthesis and 64Cu-Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold. (PubMed, ChemMedChem)
    These are based mainly on nitrogen-rich scaffolds, such as AMD070, and cyclic polyamines such as cyclam in the AMD3100 skeleton. Herein, we describe the synthesis of two novel CXCR4-directed radiopharmaceuticals, combining the AMD070 scaffold as a targeting unit, and bifunctional te1pa macrocycle as a strong 64Cu chelator. The synthesis of the conjugates and optimization of 64Cu-radiolabeling are presented, opening the way for future in vitro and in vivo studies.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor) • plerixafor
    8ms
    Drug-Drug Interaction Potential of Mavorixafor (clinicaltrials.gov)
    P1, N=36, Recruiting, X4 Pharmaceuticals
    New P1 trial
    |
    Xolremdi (mavorixafor)
    8ms
    A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=48, Recruiting, X4 Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Xolremdi (mavorixafor)
    9ms
    A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, X4 Pharmaceuticals
    New P1 trial
    |
    Xolremdi (mavorixafor)
    1year
    Grafting a chromophore on AMD070 analogues for CXCR4 bioimaging: Chemical synthesis and in vitro assessment of the inhibition properties of the CXCR4 receptor. (PubMed, Bioorg Med Chem Lett)
    Thank to their particular pharmacokinetics, the use of small organic molecules can be a very promising alternative to macromolecular targeting biomolecules (i.e. antibodies, peptides…) for specific imaging of tumours. Herein, the potential of two AMD070-like inhibitors as CXCR4-targeting units for specific imaging of cancer cells, and the influence of chromophore-grafting on their recognition properties has been investigated.
    Preclinical • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Xolremdi (mavorixafor)
    1year
    A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders (clinicaltrials.gov)
    P1/2, N=32, Completed, X4 Pharmaceuticals | Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Aug 2024 | Trial primary completion date: Jun 2025 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Xolremdi (mavorixafor)
    over1year
    A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 (clinicaltrials.gov)
    P1, N=16, Completed, X4 Pharmaceuticals | Phase classification: P1b --> P1
    Phase classification • Combination therapy
    |
    Imbruvica (ibrutinib) • Xolremdi (mavorixafor)
    over1year
    Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma. (PubMed, EJNMMI Radiopharm Chem)
    In conclusion, we compared different 177Lu-radiolabelled CXCR4-targeting peptides for their binding potential in GBM, and demonstrated their varied cytotoxic action against GBM cells in vitro, with POL3026 being the most promising, causing considerable DNA damage. Though the peptide's systemic biodistribution remains to be improved, our data demonstrate the potential of [177Lu]Lu-DOTA-POL3026 for CXCR4-TRT in the context of GBM.
    Preclinical • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    temozolomide • Xolremdi (mavorixafor) • PTX-9908
    over1year
    A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections (clinicaltrials.gov)
    P3, N=150, Recruiting, X4 Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Aug 2026 | Initiation date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jun 2025 --> Jul 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xolremdi (mavorixafor)